Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.
NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
Compound Planning Inc. grew its position in AbbVie Inc. (NYSE: ABBV) by 25.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm ow
Chase Investment Counsel Corp raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 614.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Com
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new facil
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Hillsdale Investment Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 48.7% during the third quarter, according to its most recent filing with the SEC. The institutional in
Channing Capital Management LLC lifted its position in AbbVie Inc. (NYSE: ABBV) by 10.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commiss
Bleakley Financial Group LLC increased its holdings in AbbVie Inc. (NYSE: ABBV) by 4.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology
China Universal Asset Management Co. Ltd. reduced its stake in shares of AbbVie Inc. (NYSE: ABBV) by 32.0% during the undefined quarter, according to its most recent Form 13F filing with the Securitie
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE